Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

https://www.soho2020.com/

 

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)
U

2020 SOHO Updates on AlloHSCT in AML: Are There Benefits to Chemo in Older Adults? Should We Use CC-486 in the Maintenance Setting? What Are the Outcomes With Favorable Risk? Is Intensive Induction Always Necessary?

By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Uma Borate
By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Uma Borate
111 views
November 13, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
Leukemia
11:16
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

How I Treat Older Adults With B-ALL in 2020: Is OS Better With Blina…

Feat. E. Jabbour
09:43
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Adult ALL: Is There a Role for Venetoclax in ET…

Feat. N. Jain
12:32
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on AlloHCT in R/R ALL: Is Survival Following Po…

Feat. L. Muffly
12:07
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: Are IDH Inhibitors Safe to Combine With In…

Feat. S. De Botton
10:08
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R AML: Is Gilteritinib Superior to Chemo in F…

Feat. C. Smith
16:36
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on MRD in AML: Clonal Structures/Selection of S…

Feat. V. Paresh Vyas
16:25
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on COG Approach to High-Risk ALL: What Is the Best …

Feat. J. Mcneer
13:54
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Asparaginase-Related Toxicity in AYAs With ALL: …

Feat. K. Schmiegelow
18:18
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on AYAs With ALL: How to Use an MRD Result in Patie…

Feat. A. Logan
09:34
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Acalabrutinib vs. SoC for R/R CLL: Do the Final Results of ASCEND Tr…

Feat. P. Ghia
15:18
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on CAR-T Therapy in CLL: Are Toxicities Acceptable…

Feat. E. Shpall
16:49
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Initial Therapy in CLL: Can We Consider BTK Inhi…

Feat. M. Hallek
14:36
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Treatment Consideration of CLL: Evaluation of BTK Inhibitor in the F…

Feat. J. Byrd
09:59
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Familial AML: What Are the Current Recommendatio…

Feat. C. DiNardo
12:28
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Targeting Microenvironment in R/R AML: CXCR4 Inh…

Feat. G. Uy
10:50
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Paradigm Changes in Newly Diagnosed AML: Is Venetoclax a G…

Feat. D. Pollyea
21:17
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Expert Q&A on AML: Familial AML, Targeting Microenviro…

Feat. D. Pollyea, G. Uy, C. DiNardo
33:39
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CAR-T for R/R AML: What Are the Current Limitati…

Feat. E. Budde
11:42
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Ven+Aza in Induction AML: Does This Combo Extend…

Feat. C. DiNardo
15:16
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Novel Antibodies in AML: Target Antigens, Approv…

Feat. M. Subklewe
18:48
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Germline Mutations in AML: Who Should Be Screene…

Feat. C. Lindsley
09:03
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on AYA Ph- ALL: Can an Adult Hematologist Utilize a…

Feat. S. Eldadah
14:46
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Intensive vs. Non-Intensive Approach in Adults With Ph+ ALL: Does Ch…

Feat. S. Chiaretti
16:14
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Intensive vs. Non-Intensive Approach in Adults With Ph+ ALL: Is Inte…

Feat. N. Short
15:40
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AlloHSCT in AML: Are There Benefits to Chemo in…

Feat. U. Borate
15:57
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on AlloSCT in AML: Which Older Patients in Firs…

Feat. E. Alyea
18:14
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on CD123 in AML: What Determines Sensitivity an…

Feat. A. Lane
22:39
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: Is Delaying Treatment Dangerous? What Are …

Feat. L. Michaelis
14:35
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights De-Intensified vs. Intensified Treatment in Ph+…

Feat. S. Chiaretti
16:00
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Ph+ ALL: What Is the Effect of CMR on OS? Is Hy…

Feat. N. Short
17:38
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: Are Venetoclax+HMA Combinations Safe and E…

Feat. M. Konopleva
18:42
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on CAR-T in ALL: What Are the Desired Character…

Feat. M. Pule
17:31
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R ALL: Inotuzumab Ozogamicin, Blinatumomab, &…

Feat. E. Curran
29:00
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO CP-CML Update: How Effective Is 50mg Daily Dasatinib in Ne…

Feat. M. Deininger
17:59
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CP-CML: Can Personalization of TKI Treatment Opt…

Feat. D. Rea
15:10
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on CML: Are There Differences in Treatment Respons…

Feat. J. Cortés
15:54
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CML-Like Disorders: Comparing Treatment Efficacy…

Feat. N. Cross
10:11
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: How Is Drug Development Affecting Treatmen…

Feat. A. Zeidan
15:53
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on ALL: Why Does Chemo Not Work for Older Adult…

Feat. M. Luskin
10:28
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Next Questions in ALL in 2020: Who Needs a Transplant and When? How …

Feat. S. Luger
10:26
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Next Questions in CLL in 2020: Is Ibrutinib the Best BTK Inhibitor? …

Feat. J. Brown
12:49
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CML: Is ITH Important in CML? How Does TMB Influ…

Feat. J. Radich
09:02
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO ENESTnd Trial Update on Biomarkers in CML: Does Gene Expre…

Feat. J. Radich
13:57
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Next Steps in CML: How Can We Improve the Success of Treat…

Feat. M. Deininger
15:11
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Fitness in CLL: What Is the Role of Comorbid…

Feat. A. Tedeschi
15:26
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on ALL: What Is the Role of AlloSCT in Ph+ Disease?…

Feat. J. Ribera
18:20
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MRD in CLL: How Does It Correlate With Clinical…

Feat. W. Wierda
14:16
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on BCR Inhibitors in CLL: How Do ARQ531, LOXO-305 …

Feat. P. Ghia